Impact of Cerebral Microbleeds on Cognition in Patients with Alzheimer’s Disease (4006)

Objective: We aimed to investigate the impact of cerebral microbleeds (CMBs) on the cognitive decline of patients with Alzheimer’s disease (AD) in a tertiary memory clinic. Background: CMBs are frequently observed in patients with AD, as well as in general population. They could contribute to cognitive impairment in the general population. But the impact of CMBs on cognition remained debatable in patients with AD, because of other contradictory clinical findings. Design/Methods: Patients diagnosed with AD from 1997 to 2017, with at least two consecutive, one-year-apart MMSE scores in the memory clinic of Lille were included. The following characteristics were extracted: demographic characteristics, vascular risk factors, comorbidities, medication, duration of the follow-up, successive MMSE score, dementia rating scale, APOE genotype, MRI, CSF biomarkers. We analyzed the data by a linear mixte model. Results: 369 patients were included, mostly women (58.8%). The median age at first symptom was 63.3 years old. The median MMSE score at first visit was 24 points. The median duration of follow-up was 4 years. We identified at least one CMB in 20.4% of patients, mostly single and cortical. Among patients with at least one CMB, the onset of the disease was 7 years later, the white matter hyper-intensities were more severe (43% Vs 14%, p Conclusions: In this study, patients were relatively young, and the CMB was often single. We did not show a direct impact of CMB on cognition in patients with AD. The presence of CMB was rather a marker of vascular disorder. Disclosure: Dr. Chen has nothing to disclose. Dr. Kuchcinski has nothing to disclose. Dr. Delmaire has nothing to disclose. Dr. Skrobala has nothing to disclose. Dr. DUMONT has nothing to disclose. Dr. BARUS has nothing to disclose. Dr. BERGERON has nothing to disclose. Dr. Bordet has nothing to disclose. Dr. Gautier has nothing to disclose. Dr. Pasquier has been a speaker for Roche. He is an advisory board member to API Study (Novartis) - compensation has been paid to institution.